September is Childhood Cancer Awareness Month, an observance recognized by health care institutions, advocacy organizations, patients and families around the world. While childhood cancer is rare, it is the leading cause of disease-related death past infancy in children and adolescents, according to the National Cancer Institute. Acute Lymphoblastic Leukemia (ALL)…more.
- RWHC Home
- About RWHC
- Alzheimer’s Disease
- Amyotrophic Lateral Sclerosis
- Barriers to Care
- Behavioral Health
- Big Data
- Cancer Moonshot
- CAR-T Cell Therapy
- COVID 19
- Cystic Fibrosis
- Health Disparities
- Hepatitis C
- Inflation Reduction Act
- Macular Degeneration
- Movement Disorders
As the largest professionally led nonprofit network of cancer support worldwide, the Cancer Support Community (CSC), including its Gilda’s Club affiliates, is dedicated to ensuring that all people impacted by cancer are empowered by knowledge, strengthened by action, and sustained by community. CSC achieves its mission through three areas: direct…more.
Over the past two decades there’s been tremendous progress in understanding how to harness the body’s immune system to fight cancer. Today, immunotherapy is a mainstay of cancer treatment. One of the most exciting areas of immunotherapy is CAR (chimeric antigen receptor) T-cell therapy. This treatment involves purifying a special…more.
Last year, the Multiple Myeloma Research Foundation (MMRF) launched a new, three-year strategic plan to help transform how multiple myeloma is treated and ultimately cured. One of the plan’s three strategic pillars focuses on immunotherapy, including chimeric antigen receptor T-cell (CAR-T) therapy. Real World Health Care spoke with the MMRF’s…more.
Editor’s Note: This week, Real World Health Care shares an inspirational story of a woman who was diagnosed with lymphoma and received treatment with CAR T-cell therapy. “CAR-T Cell Therapy Gave Me My Life Back” is reprinted with permission from the Association of Community Cancer Centers. Updated in April 2020,…more.
CAR T-cell therapy (CAR-T) has emerged as a highly innovative and promising option for patients with cancer. Until recently, the use of CAR-T has been restricted to small clinical trials, primarily with patients with advanced blood cancers. These trials often are conducted at large, academic medical centers in major metropolitan…more.
Editor’s Note: The following article is reprinted, with permission from Biotech Primer. The original version appeared in the Biotech Primer WEEKLY. To subscribe to the Biotech Primer WEEKLY, click here. The first (and so far, only) chimeric antigen receptor T-cell (CAR-T) therapies—tisagenlecleucel and axicabtagene ciloleucel were approved in 2017, and…more.
Topics in Focus: ALS, CAR T Therapies, Macular Degeneration and Movement Disorders The HealthWell Foundation is proud to be a founding sponsor of Real World Health Care. Since 2013, Real World Health Care (RWHC) has brought you compelling content on health care issues facing Americans. From features on the people,…more.
This week, our series on multiple myeloma continues as we talk about immunotherapies and other promising new treatments with Shaji Kumar, MD. Dr. Kumar is a professor of medicine in the division of hematology at Mayo Clinic, where he chairs the myeloma group across all three Mayo sites. Dr. Kumar…more.